In Studies of anti-inflammatory activity,
droxicam has shown itself to be as active as
piroxicam and much more active than
phenylbutazone,
isoxicam and
suprofen, both in acute studies such as
carrageenin oedema,
nystatin oedema and ultraviolet
erythema, and in longer-term tests such as that of the cotton pellet. In the studies of anti-arthritic activity, which require long-term treatment,
droxicam was as effective as
piroxicam, both on primary and on secondary lesions. The study of analgaesic activity, conducted by means of the tests of protective activity against writhing induced by
phenylbenzoquinone and
acetylcholine bromide in the mouse and by
acetic acid in the rat,
droxicam activity was superior to that of
acetylsalicylic acid,
dipyrone,
isoxicam and
phenylbutazone.
Droxicam also showed
antipyretic activity in the rat, greater than that of
acetylsalicylic acid,
dipyrone and
4-aminoantipyrine, in the brewer's yeast and Salmonella typhi tests.
Droxicam also acts as an ex vivo
platelet aggregation inhibitor in the dog. In the study of inhibition of peritoneal capillary permeability in the mouse,
droxicam was considerably more potent than
isoxicam or
phenylbutazone. Studies of general pharmacology have demonstrated that
droxicam, at high doses, has no cardiovascular or respiratory effects, and that neither does it modify behaviour in rats and mice, determined by the Irwin test. Gastrointestinal tolerance of
droxicam has been compared with that of
piroxicam, and it has been found that
droxicam is far better tolerated. The study of induction of gastrointestinal lesions in the rat demonstrated that the gastrolesive potential of
droxicam is 10 times inferior to that of
piroxicam.(ABSTRACT TRUNCATED AT 250 WORDS)